OVID Share Price Performance
US$2.30
1.99 (637.42%)
66.7% undervalued intrinsic discount
US$6.90
Fair Value
Price US$2.30
AnalystHighTarget US$6.90
Fair ValueUS$6.90
Share Pricen/a
Ovid Therapeutics Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
OVID Community Narratives
AN
Fair Value US$6.9 66.7% undervalued intrinsic discount
Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines for neurological conditions linked to neural hyperexcitability. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$6.9
66.7% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
9.65kx
Price in 2029
US$8.49
Trending Discussion
Recently Updated Narratives
AN
Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Fair Value: US$6.9 66.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ovid Therapeutics Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.13
- 100.00%
- -236.38%
- 0%
About OVID
- Founded
- 2014
- Employees
- 23
- CEO
- WebsiteView website
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
